Want to see ALVO full AI Analyst Report?
ALVO Stock Chart & Stats
$4.91
$0.02(0.65%)
At close: 4:00 PM EDT
$4.91
$0.02(0.65%)
Day’s Range― - ―
52-Week Range$2.94 - $9.25
Previous Close$3.08
Volume397.90K
Average Volume (3M)1.07M
Market Cap
$2.08B
Enterprise Value$2.63K
Total Cash (Recent Filing)$142.75M
Total Debt (Recent Filing)$1.45B
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 11, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding390,431,500
10 Day Avg. Volume1,415,206
30 Day Avg. Volume1,073,756
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-5.03
Price to Sales (P/S)2.44
P/FCF Ratio-12.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.67Price Target Upside15.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$624.48M
Bulls Say, Bears Say
Bulls Say
Broad Biosimilar Pipeline And Commercial FootprintA broad pipeline and growing portfolio of marketed products diversify future revenue opportunities. Expanding launches across Europe and Japan, alongside established market positions, can improve partner relevance and support recurring product and supply revenue.
Improved Regulatory And Manufacturing ReadinessClosure of the FDA inspection and accepted BLA resubmissions reduce a key execution barrier for U.S. approvals. Sustained regulatory readiness could enable launches, unlock milestone economics, and improve utilization of Alvotech’s manufacturing platform.
Strategic Licensing Expands Market AccessThe Lotus partnership adds U.S. co-commercialization and exclusive access to eight Asian markets while extending the pipeline into oncology and rare disease. This broadens distribution, shares commercialization responsibilities, and creates milestone and supply-revenue potential.
Bears Say
Highly Leveraged Balance SheetHigh debt combined with negative equity leaves limited balance-sheet protection if operating performance remains uneven. Refinancing needs and elevated financing costs could constrain investment, reduce strategic flexibility, and increase dependence on capital markets.
Persistent Cash Consumption And Interest BurdenThe company is not currently self-funding its operations and pipeline, while cash interest absorbs a substantial recurring outflow. Continued cash burn may require additional financing and could limit the funds available for launches, manufacturing, and research.
Weak And Volatile Operating PerformanceThe sharp revenue decline and very low product margins indicate that manufacturing disruptions and partner-order timing remain material execution risks. Reliance on lumpy licensing income makes underlying demand harder to assess and earnings less predictable.
Alvotech News
ALVO FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was $2.94 and its highest was $9.25 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is $2.08B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is Nov 11, 2026 which is in 68 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on Aug 19, 2026. The company reported -$0.092 earnings per share for the quarter, missing the consensus estimate of -$0.053 by -$0.039.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is -0.02.
How many shares outstanding does Alvotech have?
Alvotech has 390,431,500 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -$0.092 in its last earnings report, missing expectations of -$0.053. Following the earnings report the stock price went up 7.018%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in ALVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.67 (15.41% Upside)
$5.67 (15.41% Upside)
Blogger Sentiment
Bullish
ALVO Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
ALVO Company Deck
ALVO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and regulatory progress (BLA resubmissions, FDA inspection closure, manufacturing recovery, pipeline breadth and successful financing) against material near‑term financial headwinds (a 31% decline in H1 revenue, lower adjusted EBITDA, compressed product margins, increased cash interest burdens and reliance on lumpy milestone revenue). Management reaffirmed 2026 guidance and expects a strong Q4 as supply normalizes, but near‑term results remain impacted by the prior manufacturing slowdown and timing of partner orders and milestones.View all ALVO earnings summariesALVO Stock 12 Month Forecast
Average Price Target
$5.67
▲(15.41% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
1.22% Mutual Funds
6.52% Other Institutional Investors
91.72% Public Companies and
Individual Investors